Fig. 15.1 Pathophysiological time course following TBI. (Reproduced from Walker et al. [32]) Extracellular matrix destabilization occurs along with cellular dysfunction. The concentration of several matrix metalloproteinase (MMP) proteins are…

Study reference/principal investigator Study title Route Cell type/source Recipient species Therapeutic window Dose Outcome measures Follow-up/outcome measurements Results summary [10] Treatment of stroke in rat with intracarotid administration of marrow…

Study Phase Type of cells Route of injection Time after stroke Sample size Results Kondziolka et al., Neurology 2000 I Cultured neuronal cells differentiated from a human teratocarcinoma cell line…

Fig. 10.1 iNSC functioning as a cell-replacement therapy and as a producer of regenerative therapeutics for stroke patients. a A patient who has an ischemic or hemorrhagic stroke (ischemic stroke…

Fig. 1.1 Depiction of the three therapeutic approaches to acute brain injury. (Note that devices also have potential from clot-retrieval devices to devices that stimulate the sphenopalatine ganglia to blood…

Fig. 4.1 Change in the strategy for stroke. a Treatment of cardiovascular factors and administration of antiplatelet/coagulant drugs significantly contribute to the prevention of stroke onset. b In addition to…

Author, reference Study design Stroke Cell dose Manipulation Mode of application Efficacy Adverse effects Safety test Autologous bone marrow mononuclear cells Suarez-Monteaqudo, 2009 [40] No control group Treatment, n = 5 1…

Fig. 7.1 Differentiation fate of transplanted human fetal-derived NSCs and their effects on behavioral recovery after stroke. a Human fetal-derived NSCs (human nuclear antigen (HuNu)-positive cells, red) survive and migrate…

Fig. 14.1 The therapeutic potential of mesenchymal stem cells (MSC)-secreted factors for treating stroke. Following administration, MSC migrate to the site of stroke in response to chemoattractants, where they release…